Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Leukemia, Myeloid, Chronic-Phase 12Leukemia 6Gastrointestinal Stromal Tumors 6Neoplasm Metastasis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Synovitis, Pigmented Villonodular 2Recurrence 2Ovarian Neoplasms 2Hematologic Diseases 2Blast Crisis 2Substance Withdrawal Syndrome 1Peritoneal Neoplasms 1Neoplastic Processes 1Neoplasm, Residual 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Glioma 1Giant Cell Tumor of Tendon Sheath 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Cyclophosphamide 14fludarabine 12fludarabine phosphate 8Melphalan 8Brentuximab Vedotin 8Whole-Body Irradiation 7Mycophenolic Acid 7Busulfan 7Rituximab 6Tacrolimus 5Lenalidomide 4Etoposide 4isatuximab 3Sirolimus 3Mesna 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pembrolizumab 2nilotinib 2dacetuzumab 2Vincristine 2Thiotepa 2Sugars 2Stem Cell Transplantation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Ondansetron 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Diseases × nilotinib × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01844765 2021-04-22

DIALOG

Novartis

Phase 2 Completed
59 enrolled 33 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡